Alvotech and Teva ink deal with J&J on Stelara biosimilar

12 June 2023
stelara_big

Icelandic firm Alvotech (Nasdaq: ALVO) and the US unit of Israel’s Teva Pharmaceutical Industries (NYSE: TEVA) today revealed they have reached a settlement and license agreement with Johnson & Johnson (NYSE: JNJ) concerning AVT04, Alvotech’s proposed biosimilar to Stelara (ustekinumab) in the USA.

The settlement grants a license entry date for AVT04 in the US market no later than February 21, 2025. Stelara, which is indicated for a variety of autoimmune diseases including ulcerative colitis and psoriasis, generated global sales of $9.7 billion in full-year 2022, up 6.5% on 2021.

“We are delighted to have secured a US license date for our second biosimilar candidate in the US and I believe this exemplifies our multi-product approach to biosimilars globally,” said Robert Wessman, chairman and chief executive of Alvotech.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars